Combination therapy with β3‐adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: Efficacy in rats with bladder overactivity
Authors:
Open Access
- 18 February 2016
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 23 (5) , 425-430
Abstract
Objective: To investigate the efficacy of combination therapy of a selective β3‐adrenoceptor agonist (mirabegron) and muscarinic acetylcholine receptor antagonists (a selective muscarinic acetylcholine receptor2 antagonist: methoctramine hemihydrate or a selective muscarinic acetylcholine receptor3 antagonist; 4‐DAMP) compared with monotherapy of either agent in rats with oxotremorine methiodide (a non‐selective muscarinic acetylcholine receptor agonist)‐induced bladder overactivity.Methods: Cystometry was carried out in conscious female rats with intravesical instillation of oxotremorine methiodide (200 μmol/L). Either mirabegron (0.3–3 mg/kg), methoctramine (0.1–1 mg/kg) or 4‐DAMP (0.03–0.3 mg/kg) was cumulatively applied intravenously. Also, the effects of combined application of mirabegron (3 mg/kg) plus methoctramine (1 mg/kg) or 4‐DAMP (0.3 mg/kg) on cystometric parameters were compared with those of single‐agent monotherapy.Results: Intravesical instillation of oxotremorine methiodide induced bladder overactivity, as evidenced by decreases in threshold pressure and bladder capacity. In oxotremorine methiodide‐treated rats, single application of mirabegron (1, 3 mg/kg), methoctramine (0.3, 1 mg/kg) or 4‐DAMP (0.1, 0.3 mg/kg) decreased baseline pressure and increased bladder capacity. In addition, reductions in threshold pressure and maximal voiding pressure were also seen after the administration of 4‐DAMP (0.3 mg/kg). The combined treatment of mirabegron plus 4‐DAMP induced a larger increase in bladder capacity compared with monotherapy of either drug, whereas there were no significant changes in cystometric parameters between the combination therapy of mirabegron plus methoctramine and monotherapy of either drug.Conclusion: These results suggest that the combination therapy of β3‐adrenoceptor agonists plus muscarinic acetylcholine receptor3 antagonists is more effective compared with monotherapy for the treatment of bladder overactivity. In contrast, the efficacy of β3‐adrenoceptor agonists might not be increased by the addition of muscarinic acetylcholine receptor2 antagonists.Keywords
Funding Information
- Japan Society for the Promotion of Science (22591802, 15K10633)
This publication has 24 references indexed in Scilit:
- Antimuscarinics Suppress Adenosine Triphosphate and Prostaglandin E2 Release From Urothelium With Potential Improvement in Detrusor Overactivity in Rats With Cerebral InfarctionJournal of Urology, 2011
- Antimuscarinic Mechanisms and the Overactive Detrusor: An UpdateEuropean Urology, 2011
- Effects of stimulation of muscarinic receptors on bladder afferent nerves in the in vitro bladder–pelvic afferent nerve preparation of the ratBrain Research, 2010
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- Differential Roles of M2 and M3 Muscarinic Receptor Subtypes in Modulation of Bladder Afferent Activity in RatsUrology, 2010
- M 3 muscarinic receptor expression on suburothelial interstitial cellsBJU International, 2009
- Muscarinic Receptor Subtypes in the Lower Urinary TractPharmacology, 2009
- Cholinergic nitric oxide release from the urinary bladder mucosa in cyclophosphamide‐induced cystitis of the anaesthetized ratBritish Journal of Pharmacology, 2008
- Activation of Muscarinic Receptors in Rat Bladder Sensory Pathways Alters Reflex Bladder ActivityJournal of Neuroscience, 2008
- Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivoBritish Journal of Pharmacology, 1997